Novo Nordisk Acquires Etavopivat Maker Forma Therapeutics for $1.1B
Forma Therapeutics, which is currently developing an experimental treatment for sickle cell disease (SCD) called etavopivat, is being acquired by Novo Nordisk, the two companies announced. “Novo Nordisk has worked for more than 40 years to develop and deliver transformative medicines to patients around the world with…